SNDL
SNDL, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.43
+5.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 919.9M | 946.4M | 920.4M | 909.0M | 712.2M |
| Cost of Revenue | 695.7M | 687.8M | 680.1M | 718.6M | 571.8M |
| Gross Profit | 224.2M | 258.6M | 240.3M | 190.4M | 140.4M |
| Operating Expenses | |||||
| R&D Expense | 147.0K | 489.0K | 346.0K | 324.0K | 2.4M |
| SG&A Expense | 195.9M | 210.6M | 219.3M | 230.2M | 158.3M |
| General & Admin Expense | 180.9M | 196.1M | 207.3M | 215.1M | 149.8M |
| Selling & Marketing Expense | 14.9M | 14.6M | 12.0M | 15.0M | 8.4M |
| Other Expenses | 37.8M | 51.9M | 124.5M | 123.1M | 327.4M |
| Total Operating Expenses | 233.8M | 263.1M | 344.1M | 353.6M | 488.1M |
| Cost and Expenses | 929.6M | 950.8M | 1.0B | 1.1B | 1.1B |
| Operating Income (EBIT) | (9.6M) | (4.4M) | (103.8M) | (163.2M) | (347.8M) |
| Non-Operating | |||||
| Interest Income | 3.9M | 8.0M | 16.4M | 15.4M | 17.6M |
| Interest Expense | 6.2M | 7.5M | 7.7M | 7.9M | 5.9M |
| Net Interest Income | (2.3M) | 528.0K | 8.7M | 7.5M | 11.7M |
| Other Non-Op Income/Expense | (52.2M) | (11.4M) | (1.8M) | (8.8M) | (32.0M) |
| Non-Operating Income (excl Interest) | 1.1M | 3.8M | (5.9M) | 924.0K | 26.1M |
| EBT (Pre-Tax Income) | (61.8M) | (15.8M) | (105.6M) | (172.0M) | (379.8M) |
| Income Tax Expense | (3.2M) | — | (9.4M) | — | (7.3M) |
| Bottom Line | |||||
| Net Income | (58.7M) | (15.8M) | (94.8M) | (172.7M) | (335.1M) |
| Earnings from Cont. Ops | (58.7M) | (15.8M) | (96.2M) | (172.0M) | (372.4M) |
| Earnings from Discont. Ops | — | — | — | (4.5M) | — |
| Bottom Line Net Income | (58.7M) | (15.8M) | (94.8M) | (172.7M) | (335.1M) |
| Per Share | |||||
| Basic EPS | ($0.25) | ($0.06) | ($0.38) | ($0.65) | ($1.50) |
| Diluted EPS | ($0.25) | ($0.06) | ($0.38) | ($0.65) | ($1.50) |
| Revenue Per Share | $3.72 | $3.67 | $3.48 | $3.50 | $3.10 |
| Shares | |||||
| Basic Shares Outstanding | 247.0M | 258.1M | 264.2M | 259.4M | 229.9M |
| Diluted Shares Outstanding | 247.0M | 258.1M | 264.2M | 259.4M | 229.9M |
| Profitability Metrics | |||||
| EBITDA | 44.1M | 48.0M | (41.2M) | (99.1M) | (326.5M) |
| D&A | 54.8M | 56.3M | 56.7M | 64.9M | 47.3M |
| EBIT | (10.7M) | (8.3M) | (97.9M) | (164.1M) | (373.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026